Table 1

Main demographic, clinical and biochemical data of patients
With Fractures (n.18) Without Fractures (n.82) p
Age (years) 61 ± 13 61 ± 15 0.91
Male Sex (%) 61 63 0.86
Duration of RDT (months) 35 (14–75) 44 (18–101) 0.47
BMI (Kg/m2) 26.8 ± 4.8 25.1 ± 4.4 0.18
Height (cm) 159 ± 10 161 ± 10 0.48
Smokers (%) 50 48 0.85
Diabetics (%) 17 16 0.93
Treated with Beta blockers (%) 6 21 0.13
Treated with Calcitriol (%) 39 49 0.45
Treated with Ca-carbonate or Ca- acetate (%) 83 87 0.72
Treated with ESAs (%) 39 51 0.34
Hemodialysis/CAPD (n.) 15/3 51/31 0.09
History of previous fractures (%) 24 4 0.009
History of renal transplantation (%) 6 10 0.56
Haemoglobin (g/dL) 9.8 ± 2.6 10.5 ± 1.8 0.27
Serum Albumin (g/dl) 4.0 ± 0.7 3.8 ± 0.6 0.27
Serum Calcium (mmol/L) 4.5 ± 0.6 4.5 ± 0.6 0.73
Serum Phosphate (mg/dl) 6.0 ± 1.4 6.0 ± 1.6 0.92
Intact PTH (pg/mL) 319 (95–741) 135 (53–346) 0.04
intact PTH < 100 pg/ml (%) 28 46 0.15
intact PTH > 800 pg/ml (%) 22 6 0.03
Bone Alkaline phosphatase (μg/L) 15.0 (6.4-21.2) 12.7 (7.9-22.9) 0.89
Total Alkaline phospatase (UI/L) 67 (58–98) 69 (51–86) 0.88
IL-6 (pg/mL) 6.1 (3.2-8.0) 7.2 (3.3-11.0) 0.50
CRP (mg/L) 11.1 (3.5-28.2) 8.9 (3.4-19.1) 0.59
TNF-α (pg/mL) 12.0 (6.4-13.4) 7.8 (4.6-11.0) 0.02

Data are expressed as mean ± SD, median and inter-quartile range or as percent frequency, as appropriate. Patients are divided into 2 groups on the basis incident fractures occurrence. P tests the differences among the groups. Significant differences between groups are indicated in bold. Intact PTH thresholds of < 100 and >800 pg/ml identify low and high bone turn-over, respectively [18]. ESAs = erythropoiesis-stimulating-agents.

Panuccio et al.

Panuccio et al. BMC Nephrology 2012 13:134   doi:10.1186/1471-2369-13-134

Open Data